Nexgram unit Vaccines Lab inks Joint Venture Agreement with Rafarma to distribute and manufacture Covid-19 vaccines in Indonesia and ASEAN [3 Dec 2020] News Coverage

3 December 2020 (Kuala Lumpur): U.S. public listed company Rafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab Sdn Bhd, a subsidiary of Nexgram Biomedic Sdn Bhd, both wholly owned subsidiaries of Bursa Malaysia public listed Nexgram Holdings Berhad.

Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines including Covid-19. 

The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (public listed OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. 

RAFARMA plan includes the investment of approximately USD1,000,000,000 (US Dollar One Billion) for the joint venture; whereas VACCINESLAB will provide government joint venture, partnership, regulation, licenses, and incentives for the project. RAFARMA shall subscribe to 51% of JV-company in the form of preference shares, subject to the approval of such ownership by the Indonesian government.

The production capacity of the plant is designed for 500-600 million doses, covering the needs of the entire territory of Indonesia and the ASEAN countries.

About Vaccines Lab Sdn Bhd

VACCINESLAB conduct clinical trial and vaccine distribution in ASEAN countries. The firm is part of Nexgram Biomedic Sdn Bhd, the medical division of Bursa Malaysia public listed Nexgram Holdings Bhd.

About Nexgram Biomedic Sdn Bhd

NEXGRAM BIOMEDIC GROUP is a global bio pharmaceutical company dedicate to develop new medical devices, drugs, and technologies in support of innovations in the medical field. The group subsidiaries include Medical Brands Inc and Tri-G Technologies Sdn Bhd (“TRI-G”) which distribute medical devices, VaccinesLab which conduct clinical trial and vaccine distribution, Medic Data Science (“MDS”) which develops Covid- 19 screening test and vaccine record tracking App using electronic certificates (E-Certs), Tracvirus for real-time record checking in work, school and travel, NMed Industries Sdn Bhd which trade, distribute and invest in medical device and personal protection equipment manufacturing, as well as Glove Alliance Sdn Bhd in medical and disposable nitrile gloves trading, contract manufacturing and distribution.

About Rafarma Pharmaceuticals, Inc.

RAFARMA is a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-àstructure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.



The material disclosed was deem important and crucial to disclose immediately, and had been submitted to relevant authorities according to relevant Listing Rules and Regulations. As a matter of governance and duty to shareholders, the Group management does not guarantee authority review, perception, approval or intervention for such disclosure to be published in public listed company disclosure system or format, deem fit to the relevant officers, regulatory bodies, or equivalent.

The statements contained herein may contain certain forward-looking statements relating to the Group that are based on the beliefs of the Group’s management as well as assumptions made by and information currently available to the Group’s management. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. These forward-looking statements include, without limitation, statements relating to the Group’s business prospects, future developments, trends and conditions in the industry and geographical markets in which the Group operates, its strategies, plans, objectives and goals, its ability to control costs, statements relating to prices, volumes, operations, margins, overall market trends, risk management and exchange rates.

When used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to the Group or the Group’s management, are intended to identify forward-looking statements. These forward-looking statements reflect the Group’s views at the time such statement were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of the Group’s business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, the actions and developments of the Group’s competitors and the effects of competition in the industry on the demand for, and price of, the Group’s products and services, various business opportunities that the Group may or may not pursue, the Group’s ability to identify, measure, monitor and control risks in the Group’s business, including its ability to manage and adapt its overall risk profile and risk management practices, its ability to properly price its products and services, seasonal fluctuations and factors beyond the Group’s control. Subject to the requirements of the Listing Rules, the Group does not intend to update or otherwise revise such forward-looking statements, whether as a result of new information, future events or otherwise. As a result of these and other risks, uncertainties and assumptions, forward-looking events and circumstances discussed herein might not occur in the way the Group expects, or at all. Accordingly, you should not place reliance on any forward-looking information or statements. All forward-looking statements herein are qualified by reference to the cautionary statements set forth in this section.